Table 1 Tissue/plasma ratio of dolutegravir in female reproductive tract

From: Ultra-long-acting removable drug delivery system for HIV treatment and prevention

 

Day 7

Day 28

Day 84

Cervix

0.136

0.277

0.184

Uterus

0.191

0.345

0.208

Vagina

0.160

0.354

0.252

Mean ± SD

0.162 ± 0.03

0.326 ± 0.04

0.215 ± 0.03

  1. Female NSG mice (n = 18) received 250 mg/ultra-LA dolutegravir subcutaneously and dolutegravir concentration in plasma and isolated organs of the female reproductive tract was analyzed at day 7 (n = 6), 28 (n = 6), and 84 (n = 6) using a LC–MS/MS method. Mean of ratios tissue/plasma is shown
Back to article page